INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback